Knowledge, attitudes, feasibility and acceptability of take-home naloxone for people released from prison

image - Naloxone Hydrochloride
Date Commenced:
Expected Date of Completion:
Project Supporters:

Indivior untied educational grant

Drug Type:
Project Members: 
image - Sarah Larney
Senior Lecturer
Ph +61 (2) 9385 0333
image - Michael Farrell 0
Ph EA Tori Barnes: 02 9385 0292 /
image - Headshot Nielsen 2017 1cropped 0
Dr Suzanne Nielsen
Senior Research Fellow
Project Main Description: 

Overdose is a common event in the lives of opioid users, and is the leading cause of death in this population. Overdose risk is particularly elevated during the 4 weeks following release from prison.

Naloxone is a short-acting opioid antagonist that reverses respiratory depression in opioid overdose. Providing naloxone to opioid users, to be administered in the event of an overdose, prevents overdose deaths, and evidence suggests that the families and friends of opioid users can and do administer naloxone in emergency overdose situations. Programs to distribute take-home supplies of naloxone to opioid users and their close contacts are increasingly common as an overdose prevention intervention. At present, people released from prison in New South Wales (NSW) do not have ready access to take-home supplies of naloxone.

Given the increasing distribution of naloxone directly to opioid dependent people, especially people at particular risk of overdose such as recently released prisoners, this work will focus on the potential for distribution of take-home naloxone to people leaving NSW prisons. 

Project Collaborators: External: 

Justice Health and Forensic Mental Health Network


This project will assess the feasibility and acceptability of take-home naloxone for people released from NSW prisons, from the perspectives of consumers, clinicians and corrective services personnel.

Design and Method: 

This project will include an online survey of Justice Health and Forensic Mental Health Network Drug and Alcohol Service Staff; interviews with people with a history of opioid dependence recently released from prison; key expert interviews; and assessment of routinely collected data.


Data collection is underway.

Drug Type: 
Project Status: